Spero Therapeutics Reports Q2 2026 Results, Business Update

Spero Therapeutics released second-quarter 2026 financial results after the market close Wednesday and followed with a conference call at 5 p.m. ET.

Esther Rajavelu, president and chief executive officer, led the call alongside Dr. Debra Zack, chief medical officer. Rajavelu also serves as the company's chief financial officer and chief business officer. Management provided a business update alongside the results, said Shai Biran, head of investor relations. Biran opened the call and directed investors to a press release on Spero's website.

The company filed its Form 10-Q for the quarter ended June 30, 2026, with the Securities and Exchange Commission the same day. H.C. Wainwright's Raghuram Selvaraju was among analysts on the call. A replay of the call will be available on the company's website.